Trial Outcomes & Findings for Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection (NCT NCT06112353)

Patients at UCI Medical Center were assessed for eligibility from April 17, 2024 to March 4, 2026. Patients were screened for inclusion between 48 hours and 10 days prior to the scheduled procedure. Potential study participants were contacted by phone during this period and were informed about the study procedures, risks, and objectives. Patients who expressed interest in participation were approached in the preoperative area on the day of surgery to obtain formal written consent.

Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection

GI-2 recovery as defined as hour to first bowel movement and toleration of oral diet

Total cost of surgical stay

Total time patient is at hospital

Morbidity was defined as the number of participants with at least one predefined postoperative complication, including postoperative ileus, pulmonary complications, cardiovascular complications, surgical site infection, urinary tract infection, acute kidney injury, thromboembolic events, reoperation, anastomotic leak, wound dehiscence, or postoperative transfusion within 30 days after surgery. Mortality was defined as all-cause death occurring within 30 days after surgery. Complications were identified through review of the electronic medical record.

Number of participants experiencing post-reversal bradycardia prior to discharge from PACU

Time in PACU, not owing to bed availability. Defined as time to achieve a sustained Aldrete score ≥8.

Time for patient to be able to get out of bed and walk post surgically

Total amount of IV fluids administered during and after surgery through PACU stay.

Number of Participants Experiencing PONV

Open-label sugammadex exposure includes patients who received rescue sugammadex after the blinded study medication administration and patients who received open-label sugammadex as the sole agent used for antagonism of neuromuscular blockade.